Revvity Outperforms BioNexus Gene Lab in Key Metrics

Analysts see more upside potential in the larger, more diversified medical company

Apr. 17, 2026 at 10:20pm

Got story updates? Submit your updates here. ›

An extreme close-up photograph of intricate medical diagnostic machinery and instrumentation, dramatically lit to emphasize the complex, industrial nature of the healthcare industry's financial and technological infrastructure.Advanced medical technology and equipment serve as a visual metaphor for the financial strength and operational efficiency of leading healthcare companies.Waltham Today

Revvity (NYSE:RVTY) and BioNexus Gene Lab (NASDAQ:BGLC) are both medical companies, but a comparison of the two businesses shows Revvity has stronger financials, lower volatility, and a more favorable analyst consensus rating.

Why it matters

The analysis provides insight into the relative strengths and weaknesses of these two medical industry players, which can help investors make more informed decisions about which stock may be the better long-term investment.

The details

Revvity has significantly higher institutional ownership at 86.7% compared to just 18.9% for BioNexus. Revvity also has stronger profitability metrics, with a net margin of 11.9% versus 5.1% for BioNexus. Additionally, Revvity's stock is less volatile, with a beta of 1.13 versus 4.98 for BioNexus. Analysts are also more bullish on Revvity, with a consensus price target suggesting 17.2% upside potential compared to just 2.9% for BioNexus.

  • Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
  • BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

The players

Revvity, Inc.

A provider of health sciences solutions, technologies, and services in the Americas, Europe, and Asia, with business segments in Life Sciences and Diagnostics.

BioNexus Gene Lab Corp.

A Malaysian company that sells chemical raw material products and is developing non-invasive liquid biopsy tests for early disease detection.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights Revvity's stronger financial position, lower volatility, and more favorable analyst sentiment compared to the smaller and more speculative BioNexus Gene Lab. Investors looking for a more stable and diversified medical industry play may find Revvity the more compelling investment option.